| 29.7 -0.71 (-2.33%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.44 | 1-year : | 42.56 |
| Resists | First : | 31.2 | Second : | 36.44 |
| Pivot price | 29.43  |
|||
| Supports | First : | 28.02 | Second : | 26.07 |
| MAs | MA(5) : | 30.16  |
MA(20) : | 28.81 |
| MA(100) : | 29.06 |
MA(250) : | 30.95 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 73.5 |
D(3) : | 77.1 |
| RSI | RSI(14): 58.7 |
|||
| 52-week | High : | 36.1 | Low : | 26.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SNN ] has closed below upper band by 43.3%. Bollinger Bands are 55.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 30.15 - 30.33 | 30.33 - 30.48 |
| Low: | 29.28 - 29.46 | 29.46 - 29.64 |
| Close: | 29.43 - 29.74 | 29.74 - 30.01 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Fri, 30 Oct 2026
Las Vegas Raiders-New York Jets FEED Topic: Monitoring Geno Smith’s ‘revenge game’ - Yahoo Sports
Fri, 30 Oct 2026
Philadelphia Eagles' DeVonta Smith, Dontayvion Wicks both out again vs. Washington Commanders in Week 8 - CBS News
Fri, 30 Oct 2026
Tyler Smith, Cowboys offensive line looking to build momentum vs. Cardinals - Dallas Cowboys | Official Site of the Dallas Cowboys
Fri, 30 Oct 2026
LDS founder Joseph Smith’s presidential campaign and the not-so-secret ballots in Nauvoo - The Salt Lake Tribune
Fri, 30 Oct 2026
Saquon Barkley set to play, DeVonta Smith ruled out - NBC Sports
Fri, 30 Oct 2026
DeVonta Smith set to miss Week 8 - Yahoo Sports
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 419 (M) |
| Shares Float | 2,110 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 11.4 (%) |
| Shares Short | 4,660 (K) |
| Shares Short P.Month | 6,240 (K) |
| EPS | 1.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.43 |
| Profit Margin | 10 % |
| Operating Margin | 14.4 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 11.8 % |
| Qtrly Rev. Growth | 4.5 % |
| Gross Profit (p.s.) | 10.29 |
| Sales Per Share | 15.05 |
| EBITDA (p.s.) | 3.29 |
| Qtrly Earnings Growth | 5.6 % |
| Operating Cash Flow | 1,340 (M) |
| Levered Free Cash Flow | 1,060 (M) |
| PE Ratio | 20.2 |
| PEG Ratio | 1.2 |
| Price to Book value | 12.22 |
| Price to Sales | 1.97 |
| Price to Cash Flow | 9.27 |
| Dividend | 0.31 |
| Forward Dividend | 0 |
| Dividend Yield | 1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|